Skip to main content
. 2019 Jan 25;9(2):12. doi: 10.1038/s41408-019-0175-y

Table 2.

Univariate and multivariable analysis of clinical and genetic predictors of leukemic transformation in 1306 patients with primary myelofibrosis

Predictors of leukemic transformation in the first 5 years of diagnosis (Logistic regression analysis) Risk factors for leukemia-free survival (Cox analysis)
Variables Univariate analysis P value (OR, 95% CI) Multivariable analysis P value (OR, 95% CI) Univariate analysis P value (HR, 95% CI) Multivariable analysis P value (HR, 95% CI)
Age in years <0.001 0.01 (1.02, 1–1.03)
Age > 70 years 0.003 (2.1, 1.3–3.3) <0.001 (13.3, 3.5–51.2) 0.4 (1.2, 0.8–1.7) 0.03 (2.1, 1.1–3.8)
Gender (Male) <0.001 (2.8, 1.7–4.6) 0.01 (6.9, 1.6–30.2) 0.002 (1.7, 1.2–2.5)
Sex and severity adjusted anemia
N” evaluable = 1298
Moderate/Severe anemia < 0.001 (3.1, 2.0–4.9) 0.02 (3.6, 1.2–10.7) < 0.001 (1.8, 1.3–2.6) 0.02 (1.9, 1.1–3.3)
No/Mild anemia Reference Reference
Platelets, ×109/l “N” evaluable = 1299 <0.001 0.05 (0.2, 0.04–1.03)
Platelets<100 × 109/l “N” evaluable = 1299 <0.001 (3.6, 2.1–6.1) 0.001 (1.9, 1.3–2.8)
Leukocytes, ×109/l “N” evaluable = 1298 <0.001 <0.001 (17, 3.9–51.4)
Leukocytes > 25 × 109/l “N” evaluable = 1298 0.002 (3.4, 1.8–6.3) 0.01 (1.8, 1.1–2.8)
Circulating blasts % “N” evaluable = 1283 <0.001 <0.001 (18.5, 7.3–41.6)
Circulating blasts ≥ 3% “N” evaluable = 1283 <0.001 (3.6, 2.2–6.1) 0.009 (5.5, 1.5–19.6) <0.001 (2.6, 1.7–3.7) 0.001 (3.3, 1.6–6.2)
Palpable splenomegaly “N” evaluable = 1260 0.4 (0.8, 0.5–1.3) 0.3 (0.8, 0.6–1.2)
Bone marrow fibrosis grade (2 or above) “N” evaluable = 793 0.5 (0.8, 0.4–1.5) 0.6 (0.9, 0.6–1.5)
Constitutional symptoms “N” evaluable = 1302 <0.001 (2,5, 1.5–3.9) 0.04 (3.1, 1.0–9.2) 0.009 (1.6, 1.1–2.3)
Any thrombosis at or prior to diagnosis “N” evaluable = 1299 0.3 (0.7, 0.3–1.4) 0.08 (0.6, 0.4–1.1)
Venous thrombosis at or prior to diagnosis “N” evaluable = 1298 0.2 (0.5, 0.1–1.4) 0.04 (0.4, 0.2–1)
Arterial thrombosis at or prior to diagnosis “N” evaluable = 1299 0.8 (1.1, 0.5–2.2) 0.7 (0.9, 0.5–1.6)
Presence of very high-risk (VHR) karyotype <0.001 (10.9, 3.7–32.3) 0.005 (57.6, 3.3–994) <0.001 (3.6, 1.9–6.3)
Karyotype
N” evaluable = 1218
VHR <0.001 (12, 4–35.7) <0.001 (3.9, 2–7)
Unfavorable 0.08 (1.6, 0.9–2.9) 0.05 (1.6, 1–2.9)
Favorable Reference Reference
Driver mutational status
N” evaluable = 897
JAK2 0.7 (0.9, 0.5–1.5) 0.2 (0.7, 0.5–1.1)
CALR 0.2 (0.6, 0.3–1.3) 0.9 (0.9, 0.6–1.6)
MPL 0.5 (1.3, 0.4–3.7) 0.5 (1.3, 0.5–2.6)
Triple-negative 0.05 (2.2, 0.9–4.7) 0.06 (1.9, 0.9–3.3)
CALR type 1/like absent 0.045 (2.2, 1.0–4.9) 0.7 (1.1, 0.7–1.8)
Mutations
ASXL1 mutated “N” evaluable = 596 <0.001 (3.8, 2–7.2) <0.001 (15.1, 4.0–56.7) <0.001 (2.2, 1.4–3.5) 0.01 (2.0, 1.2–3.3)
SRSF2 mutated “N” evaluable = 597 <0.001 (8.04, 3.7–17.2) 0.002 (8.5, 2.2–32.2) <0.001 (3.5, 2.1–5.7) 0.001 (3.0, 1.6–5.3)
IDH1 mutated “N” evaluable = 479 0.005 (23.5, 2.5–217) 0.002 (78.4, 5.3–1153) 0.006 (6.2, 1.9–15.4) 0.03 (4.3, 1.2–11.7)
IDH2 mutated “N” evaluable = 479 0.002 (9.9, 2.3–43.7) 0.01 (3.1, 1.1–7.1)
EZH2 mutated “N” evaluable = 452 0.4 (1.9, 0.4–9.7) 0.7 (1.3, 0.2–4.2)
U2AF1 mutated “N” evaluable = 579 0.09 (2, 0.9–4.6) 0.3 (1.4, 0.7–2.7)
U2AF1 Q157 mutated “N” evaluable = 579 0.3 (1.8, 0.6–5.9) 0.5 (1.4, 0.5–3)

Abbreviation: OR odds ratio, HR hazard ratio, CI confidence interval

Bold values indicates significance indicator